Heath Lukatch Sells 500 Shares of Inogen Inc (INGN) Stock

Share on StockTwits

Inogen Inc (NASDAQ:INGN) Director Heath Lukatch sold 500 shares of the business’s stock in a transaction dated Tuesday, November 6th. The stock was sold at an average price of $193.97, for a total transaction of $96,985.00. Following the sale, the director now directly owns 1,489 shares in the company, valued at approximately $288,821.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Heath Lukatch also recently made the following trade(s):

  • On Friday, October 5th, Heath Lukatch sold 500 shares of Inogen stock. The stock was sold at an average price of $218.23, for a total transaction of $109,115.00.
  • On Thursday, September 6th, Heath Lukatch sold 500 shares of Inogen stock. The stock was sold at an average price of $261.54, for a total transaction of $130,770.00.

INGN stock opened at $148.51 on Friday. The stock has a market cap of $3.33 billion, a P/E ratio of 113.37, a P/E/G ratio of 3.06 and a beta of 1.56. Inogen Inc has a 52 week low of $111.49 and a 52 week high of $287.79.

Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, November 6th. The medical technology company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.21. The firm had revenue of $95.29 million for the quarter, compared to the consensus estimate of $90.94 million. Inogen had a net margin of 12.28% and a return on equity of 18.91%. The firm’s revenue was up 38.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.33 earnings per share. As a group, analysts forecast that Inogen Inc will post 2.1 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. CIBC World Markets Inc. lifted its holdings in shares of Inogen by 71.0% in the third quarter. CIBC World Markets Inc. now owns 14,593 shares of the medical technology company’s stock valued at $3,562,000 after purchasing an additional 6,057 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Inogen by 1.2% in the third quarter. Bank of New York Mellon Corp now owns 207,765 shares of the medical technology company’s stock valued at $50,720,000 after purchasing an additional 2,422 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Inogen by 85.2% in the third quarter. Janus Henderson Group PLC now owns 7,810 shares of the medical technology company’s stock valued at $1,907,000 after purchasing an additional 3,593 shares in the last quarter. AXA purchased a new stake in shares of Inogen in the third quarter valued at about $1,587,000. Finally, Alliancebernstein L.P. lifted its holdings in shares of Inogen by 43.3% in the third quarter. Alliancebernstein L.P. now owns 373,794 shares of the medical technology company’s stock valued at $91,251,000 after purchasing an additional 113,024 shares in the last quarter. 96.67% of the stock is currently owned by institutional investors.

INGN has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of Inogen from a “hold” rating to a “buy” rating and set a $290.00 price objective on the stock in a report on Thursday, September 27th. BidaskClub downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a report on Thursday, September 20th. Stifel Nicolaus set a $258.00 price objective on shares of Inogen and gave the stock a “buy” rating in a report on Tuesday, August 21st. Needham & Company LLC downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating and boosted their price objective for the stock from $254.00 to $296.00 in a report on Monday, September 10th. Finally, ValuEngine downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. Inogen presently has an average rating of “Buy” and a consensus target price of $244.67.

TRADEMARK VIOLATION WARNING: “Heath Lukatch Sells 500 Shares of Inogen Inc (INGN) Stock” was reported by BBNS and is the sole property of of BBNS. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://baseballnewssource.com/2018/11/10/heath-lukatch-sells-500-shares-of-inogen-inc-ingn-stock/2972048.html.

About Inogen

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading: How Do You Make Money With Penny Stocks?

Insider Buying and Selling by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.